WALTHAM, Mass., Oct. 29, 2019 (GLOBE NEWSWIRE) — Chiasma, Inc. (Nasdaq: CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today announced that it will host a conference call and live audio webcast on Tuesday, November 5, 2019 at 5:00 p.m. Eastern Time to discuss financial results for the quarter and nine months ended September 30, 2019 and to provide a business update.
Conference Call DetailsTuesday, November 5th @ 5pm Eastern TimeA live audio webcast of the call may also be accessed under “Events & Presentations” on the News & Investors section of the Company’s website, http://ir.chiasmapharma.com/events-presentations. An archived replay of webcast will be available on the Company’s website approximately two hours after the event. The archived webcast will be available for one year.About ChiasmaChiasma is focused on improving the lives of patients who face challenges associated with their existing treatments for rare and serious chronic diseases. Employing its Transient Permeability Enhancer (TPE®) technology platform, Chiasma seeks to develop oral medications that are currently available only as injections. In July 2019, the Company reported positive topline data from its CHIASMA OPTIMAL Phase 3 clinical trial for its octreotide capsules product candidate, conditionally trade named Mycapssa, for the maintenance therapy of adult patients with acromegaly in whom prior treatment with somatostatin analogs has been shown to be effective and tolerated. Prior to trial initiation, the Company reached agreement with the FDA on the design of the trial through a special protocol assessment. Chiasma is headquartered in Waltham, MA with a wholly-owned subsidiary in Israel. Mycapssa, TPE and CHIASMA are registered trademarks of Chiasma. For more information, please visit the Company’s website at www.chiasma.com.Contact:
Ashley R. Robinson
LifeSci Advisors, LLC
617-430-7577
arr@lifesciadvisors.com
Bay Street News